✦ LIBER ✦

20 An audit of docetaxel for 2nd line treatment of patients with advanced non small cell lung cancer (NSCLC): toxicities and outcomes in NHS Tayside 2005–2010

✍ Scribed by Capaldi, S.; Lord, H.; Rankin, E.M.; Brown, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

47 How are we doing? Clinical audit of p

✍ Costantino, S.; Lord, H. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Phase II study of docetaxel (DOC) and ca

✍ van Putten, J.W.G; Slebos, D.J; Groen, H.J.M 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 113 KB

A phase II study of docetaxel (D) and ge

✍ Agelaki, S.; Papadakis, E.; Tsiafaki, X.; Rapti, A.; Toubis, M.; Bania, E.; Kalb 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 158 KB

O-1 A phase III trial comparing weekly a

✍ Schuette, Wolfgang; Nagel, Sylke; Lautenschlaeger, C.; Serke, Monika; Wollschlae 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 167 KB

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN36 ECONOMIC EVALUATION OF ERLOTINIB,

✍ S Capri; A Morabito; G Carillio; F Grossi; R Longo; G Cerea; F Rossetti 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB